CMP Pharma, Inc. Announces Unit Dose Packaging for CaroSpir, The First and Only FDA-Approved Spironolactone Oral Suspension.
ENPNewswire-October 19, 2021--CMP Pharma, Inc. Announces Unit Dose Packaging for CaroSpir, The First and Only FDA-Approved Spironolactone Oral Suspension
(C)2021 ENPublishing - http://www.enpublishing.co.uk
Release date- 18102021 - Farmville, NC. - CMP Pharma announced that CaroSpir (Spironolactone Oral Suspension, 25 mg/5 mL), the first and only FDA-approved oral liquid dosage form of the potassium-sparing diuretic spironolactone, is now available in a unit dose cup.
CaroSpir ensures that adult patients who have difficulty swallowing or who cannot swallow tablets receive a stable and consistent dose of spironolactone every time without the concerns associated with unapproved compounded formulations. The new unit dose package makes administering CaroSpir even easier and more convenient for health care providers.
The 5 mL cups contain a single pre-measured dose of CaroSpir, helping health care providers save time, minimize product waste, reduce risk associated with handling of medications that should not be crushed and reduce the burden of administration. The single dose package allows for a more efficient use of nursing resources by eliminating the time needed for compounding or pouring at the bedside.
'CaroSpir is a convenient, safe, and approved liquid option for patients who need it, and the new unit dose cup makes administering CaroSpir even easier for busy healthcare workers,' said Gerald Sakowski, CEO of CMP Pharma, Inc.
Unit dose CaroSpir is available in cartons of 10 cups, 5mL per cup. CaroSpir is also available in 118 mL and 473 mL bottles. All formulations have 24-month dating and are manufactured and tested at CMP Pharma's FDA-inspected GMP manufacturing facility in Farmville, North Carolina.
The new CaroSpir unit dose is now available through normal retail distribution. For more information, contact CMP Pharma at 252-753-7111 or visit CaroSpir.com.
About CaroSpir
CaroSpir (spironolactone oral suspension) is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema and to reduce the need for hospitalization for heart failure, and is usually administered in conjunction with other therapies. CaroSpir is also indicated for use as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents, as part of comprehensive cardiovascular risk management. Lastly, CaroSpir is indicated for the...
To continue reading
Request your trial